Insights into Natriuretic Peptides in Heart Failure: an Update

Overview

Journal Curr Heart Fail Rep

Publisher Current Science

Date 2008 Sep 4

PMID 18765080

Citations 5

Authors

Josef Korinek

Guido Boerrigter

Selma F Mohammed

John C Burnett Jr

Affiliations

Soon will be listed here.

Abstract

Natriuretic peptides (NPs) secreted by the heart in response to volume overload are pleiotropic molecules with vasodilating, diuretic, natriuretic, antiproliferative, and antifibrotic actions. Functioning of the NP system is altered in congestive heart failure (CHF), suggesting that support of the NP system might be beneficial in treatment of acute and chronic CHF. Several approaches alone or in combination with other pharmacologic therapies have been shown to enhance function of the NP system: direct administration of native and designer NPs, inhibition of degradation of NPs and their second messenger (cyclic guanosine monophosphate ), and stimulation of cGMP generation. Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed. Moreover, further research is warranted to identify the stages and etiologies of CHF that may profit from NP therapy.

Citing Articles

Measuring lung water adds prognostic value in heart failure patients undergoing cardiac magnetic resonance.

Rocha B, Cunha G, Freitas P, Lopes P, Santos A, Guerreiro S Sci Rep. 2021; 11(1):20162.

PMID: 34635767 PMC: 8505633. DOI: 10.1038/s41598-021-99816-6.

A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure.

Testani J, Damman K, Brisco M, Chen S, Laur O, Kula A J Card Fail. 2014; 20(12):912-9.

PMID: 25152498 PMC: 4292792. DOI: 10.1016/j.cardfail.2014.08.008.

CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.

McKie P, Sangaralingham S, Burnett Jr J Curr Heart Fail Rep. 2010; 7(3):93-9.

PMID: 20582736 DOI: 10.1007/s11897-010-0016-6.

Systems biology and heart failure: concepts, methods, and potential research applications.

Adams K Heart Fail Rev. 2009; 15(4):371-98.

PMID: 19396630 DOI: 10.1007/s10741-009-9138-x.

Nesiritide in acute decompensated heart failure: current status and future perspectives.

Mohammed S, Korinek J, Chen H, Burnett J, Redfield M Rev Cardiovasc Med. 2008; 9(3):151-8.

PMID: 18953274 PMC: 4090946.

References

Lisy O, Huntley B, McCormick D, Kurlansky P, Burnett Jr J . Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008; 52(1):60-8. PMC: 2575424. DOI: 10.1016/j.jacc.2008.02.077. View

Hauptman P, Schnitzler M, Swindle J, Burroughs T . Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA. 2006; 296(15):1877-84. PMC: 2840641. DOI: 10.1001/jama.296.15.1877. View

Arora R, Venkatesh P, Molnar J . Short and long-term mortality with nesiritide. Am Heart J. 2006; 152(6):1084-90. DOI: 10.1016/j.ahj.2006.07.002. View

Brandt I, Lambeir A, Ketelslegers J, Vanderheyden M, Scharpe S, De Meester I . Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2005; 52(1):82-7. DOI: 10.1373/clinchem.2005.057638. View

Huntley B, Sandberg S, Noser J, Cataliotti A, Redfield M, Matsuda Y . BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol. 2006; 209(3):943-9. DOI: 10.1002/jcp.20793. View

Forfia P, Lee M, Tunin R, Mahmud M, Champion H, Kass D . Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007; 49(10):1079-88. DOI: 10.1016/j.jacc.2006.08.066. View

Brunner-La Rocca H, Kaye D, Woods R, Hastings J, Esler M . Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001; 37(5):1221-7. DOI: 10.1016/s0735-1097(01)01172-x. View

Rouleau J, Pfeffer M, Stewart D, Isaac D, Sestier F, Kerut E . Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000; 356(9230):615-20. DOI: 10.1016/s0140-6736(00)02602-7. View

Joseph R, Pahari S, Hodgson W, Kini R . Hypotensive agents from snake venoms. Curr Drug Targets Cardiovasc Haematol Disord. 2004; 4(4):437-59. DOI: 10.2174/1568006043335808. View

10.

Cataliotti A, Chen H, Redfield M, Burnett Jr J . Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin. 2007; 2(3):269-76. DOI: 10.1016/j.hfc.2006.09.002. View

11.

Wang D, Dowling T, Meadows D, Ayala T, Marshall J, Minshall S . Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004; 110(12):1620-5. DOI: 10.1161/01.CIR.0000141829.04031.25. View

12.

Patel J, Valencik M, Pritchett A, Burnett Jr J, McDonald J, Redfield M . Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol. 2005; 289(2):H777-84. DOI: 10.1152/ajpheart.00117.2005. View

13.

Singh G, Kuc R, Maguire J, Fidock M, Davenport A . Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res. 2006; 99(2):183-90. DOI: 10.1161/01.RES.0000232322.06633.d3. View

14.

Arora S, Clarke K, Srinivasan V, Gradman A . Effect of nesiritide on renal function in patients admitted for decompensated heart failure. QJM. 2007; 100(11):699-706. DOI: 10.1093/qjmed/hcm089. View

15.

Chen H, Lainchbury J, Harty G, Burnett Jr J . Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation. 2002; 105(8):999-1003. DOI: 10.1161/hc0802.104282. View

16.

Costanzo M, Johannes R, Pine M, Gupta V, Saltzberg M, Hay J . The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated.... Am Heart J. 2007; 154(2):267-77. DOI: 10.1016/j.ahj.2007.04.033. View

17.

Cataliotti A, Burnett Jr J . Natriuretic peptides: novel therapeutic targets in heart failure. J Investig Med. 2005; 53(7):378-84. DOI: 10.2310/6650.2005.53711. View

18.

Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T . Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 2002; 71(23):2701-12. DOI: 10.1016/s0024-3205(02)01990-2. View

19.

Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi M . Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007; 50(22):2136-44. DOI: 10.1016/j.jacc.2007.07.078. View

20.

Chen H, Schirger J, Chau W, Jougasaki M, Lisy O, Redfield M . Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999; 100(24):2443-8. DOI: 10.1161/01.cir.100.24.2443. View